Catalent
CTLT
#1737
Rank
NZ$19.94 B
Marketcap
NZ$109.88
Share price
0.00%
Change (1 day)
15.86%
Change (1 year)
Catalent is an American pharmaceutical contract research and development company.

Catalent (CTLT) - Total debt

Total debt on the balance sheet as of September 2024 : NZ$8.56 Billion

According to Catalent's latest financial reports the company's total debt is NZ$8.56 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Catalent - Total debt on balance sheet (from 2013 to 2024)

Total debt by year

Year Total debt Change
2023-06-30NZ$7.92 B17.28%
2022-06-30NZ$6.75 B45.13%
2021-06-30NZ$4.65 B-0.99%
2020-06-30NZ$4.70 B6.81%
2019-06-30NZ$4.40 B9.54%
2018-06-30NZ$4.01 B41.46%
2017-06-30NZ$2.84 B8.96%
2016-06-30NZ$2.60 B-5.92%
2015-06-30NZ$2.77 B-10.41%
2014-06-30NZ$3.09 B-11.08%
2013-06-30NZ$3.47 B4.03%
2012-06-30NZ$3.34 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Supernus Pharmaceuticals
SUPN
NZ$73.06 M-99.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Aerie Pharmaceuticals
AERI
NZ$0.58 B-93.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Jazz Pharmaceuticals
JAZZ
NZ$9.39 B 9.73%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Intercept Pharmaceuticals
ICPT
NZ$0.38 B-95.47%๐Ÿ‡บ๐Ÿ‡ธ USA